Olanzapine with first-line immunotherapy for advanced lung cancer trial
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding the drug olanzapine to standard first-line immunotherapy (with or without chemotherapy) can help people with advanced lung cancer that does not have an EGFR mutation. It aims to improve treatment outcomes and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 74 years old.
- Your lung cancer is stage IV (has spread) and does not have an EGFR mutation.
- You have not had any prior treatment for lung cancer (like chemotherapy, immunotherapy, or radiation).
- You are able to take oral medication and have no serious stomach or gut problems.
- You have adequate organ function (kidney, liver, bone marrow) and no serious heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (DZD9008 and AZD4205) for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This Phase 1 study tests pembrolizumab (an immunotherapy) given together with a chemotherapy drug to treat non-small cell lung cancer that is locally advanced or has spread. It’s aimed at people who can handle treatment with an ECOG performance status of 2, including some with certain types of brain metastases.
This study tests whether a medicine called olanzapine can improve survival in people with advanced cancers of the upper digestive system or lungs. Olanzapine may help with appetite and weight, which are common problems in these cancers.
This Phase 2 trial tests whether olanzapine can help people with advanced cancer who are losing weight and not eating enough. It looks for improvements in appetite and weight while you receive your first-line palliative cancer treatment.
This trial tests whether a medication called olanzapine can help reduce nausea and loss of appetite in patients receiving chemotherapy before surgery for stomach cancer. The goal is to help you feel better and maintain nutrition during your cancer treatment.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.